key: cord-1031856-t1w54cdd
authors: Lee, Eun‐Ju; Cines, Douglas B.; Gernsheimer, Terry; Kessler, Craig; Michel, Marc; Tarantino, Michael D.; Semple, John W.; Arnold, Donald M.; Godeau, Bertrand; Lambert, Michele P.; Bussel, James B.
title: Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination
date: 2021-03-09
journal: Am J Hematol
DOI: 10.1002/ajh.26132
sha: 5ad89063abb2a2043ca77a48aa155dfc8f7b0927
doc_id: 1031856
cord_uid: t1w54cdd

nan

providers. These cases were investigated as suspicious for new onset, post-vaccination secondary ITP; we could not exclude exacerbation of clinically undetected ITP. Search terms relating to "decreased platelet count", "immune thrombocytopenia", "hemorrhage", "petechiae", and "contusion" were utilized to identify cases reported in VAERS.

The reports describing 19 of 20 patients included age (range 22-73 years old; median 41 years) and gender (11 females and 8 males). Nine received the Pfizer vaccine and 11 received the Moderna vaccine. All 20 patients were hospitalized and most patients presented with petechiae, bruising or mucosal bleeding (gingival, vaginal, epistaxis) with onset of symptoms between 1-23 days (median 5 days) post vaccination. Platelet counts at presentation were available for all 20 cases with the majority being at or below 10 × 10 9 /L (range 1-36 × 10 9 /L; median 2 × 10 9 /L).

One patient had known ITP in remission; another had mildmoderate thrombocytopenia in 2019 with note of positive anti-platelet antibodies, a third had previous mild thrombocytopenia (145 × 10 9 /L) while a fourth had inherited thrombocytopenia with baseline platelet counts of 40-60 × 10 9 /L. Three other patients had known autoimmune conditions including hypothyroidism, Crohns disease, or positive tests for anti-thyroglobulin antibodies. Treatment for suspected ITP was described in 15 of the cases, including corticosteroids n = 14, intravenous immune globulin (IVIG) n = 12, platelet transfusions n = 8, rituximab n = 2, romiplostim = 1, vincristine = 1, and aminocaproic acid (Amicar) n = 1; combination therapy was used in mL). The patient was diagnosed with myocarditis but did not require treatment for thrombocytopenia. Her platelets were 61 × 10 9 /L on discharge, but subsequent platelet counts were not reported. The third is a patient without age or gender reported who was found to have thrombocytopenia, neutropenia and a pulmonary embolism at an unspecified time following the Pfizer vaccine. This patient was hospitalized and passed away; no additional details were available. A fourth patient, a 37-year-old man, had "thrombocytopenia requiring hospitalization, meds and platelet infusion" 4 days following the Moderna vaccine with no details regarding presenting symptoms, platelet count, treatment or outcome. The last patient is an 80 year-old man with multiple medical problems including recent transcatheter aortic valve replacement, hypothyroidism, and diverticulosis who presented 6 days after the Pfizer vaccine with bloody diarrhea, hemoglobin 8.7 g/dL and platelets 60 × 10 9 /L. He received several units of packed red blood cells and two units of platelets with improvement to 101 × 10 9 /L and was discharged 5 days later. There were a handful of reports with minimal additional details alluding to a male who passed away in December from brain hemorrhage following the Pfizer vaccinethese could be describing the index patient. We did not attempt to obtain information on patients with pre-existing active ITP who received a SARS-CoV-2 vaccine for this report.

We identified additional reports of post-vaccination bruising or bleeding unrelated to the injection site, but no mention of platelet counts, or thrombocytopenia, was provided. Note, VAERS was last accessed on January 29, 2021 for this search. Fourteen patients reported "petechiae"/"bruising" of whom three were evaluated in the office and one presented to the emergency room. There have been 51 reports of" bleeding"/"hemorrhage" (vaginal n = 11, conjunctival n = 13, cerebral n = 6, gingival n = 2, gastrointestinal n = 5, epistaxis n = 12, and cutaneous n = 2). There were 31 patients who did not seek additional evaluation, seven were seen via office visits, while 13 presented to the emergency room or were hospitalized. Two patients passed away in the hospital. No additional details are available.

Are these case of primary ITP coincident with or secondary ITP as a result of vaccination? In either case, the clinical presentations and the favorable response to "ITP-directed" therapies in most of the treated patients, such as corticosteroids and IVIG suggest an antibody-mediated platelet clearance mechanism that is operative in ITP. 11 In the absence of pre-vaccination platelet counts and given the variable time post vaccination to discovery of thrombocytopenia, it is impossible to precisely estimate the incidence of secondary ITP post SARS-CoV-2 vaccination at this time. However, it is notable that all but one of the cases identified thus far occurred after the initial dose of SARS-CoV-2 vaccine. One would assume that if the vaccination was unrelated to development of ITP, case occurrences would divide more evenly between the two doses. It is also likely that the actual incidence of thrombocytopenia, including mild asymptomatic cases, may be higher and go unreported.

Even in view of the uncertain relationship between SARS-CoV-2 vaccination and secondary ITP, it is worth considering possible mechanisms by which this might occur. Thrombocytopenia has been reported after treatment with some anti-sense oligonucleotides, 12, 13 but it would seem that a far higher, sustained level of RNA reaching dendritic cells in lymph nodes and elsewhere would be required to generate an immune response than is likely seen based on a single intramuscular injection. This is also inconsistent with the very rapid onset of thrombocytopenia in the index and additional cases. The reported cases also provide insight into diagnosis and treatment. Most of the patients responded to treatment with corticosteroids and IVIG but showed little benefit from platelet transfusion, a pattern consistent with that of ITP. There was no response in the two patients treated with rituximab but they were only evaluable for up to 2 weeks; in addition, rituximab would impair the response to vaccination, if given within days to 2 weeks of the vaccination and for at least 4-6 months subsequently. The first of two patients (with sufficient information available) continued to have a platelet count of 1-2 × 10 9 /L and died of intracranial bleeding 16 days post vaccination and 13 days post presentation of ITP despite receiving platelet transfusions, steroids, IVIG, and rituximab. The second patient presented 1 day after vaccination and still had a count of 1 × 10 9 /L 7 days later despite receiving the same combination of the four ITP treatments; however, she responded following addition of vincristine and romiplostim. The suggestion might be (from this very limited information) to give IVIG and high dose steroids as initial treatment. If this does not work and the platelet count remains very low, it would seem appropriate to institute other treatments within the first week including a thrombopoietic agent perhaps starting above the lowest dose often recommended to initate therapy and potentially vinca alkaloids depending upon response. Excluding rituximab from initial treatment seems appropriate in most cases given that response can take up to 8 weeks 18 and response to vaccination can be impaired. Once a platelet response is seen, patients could be managed as if they were typical cases of primary ITP. Whether such cases will prove to be self-limiting or persist and lead to chronic ITP remains uncertain.

In summary, we cannot exclude the possibility that the Pfizer and Moderna vaccines have the potential to trigger de novo ITP (including clinically undiagnosed cases), albeit very rarely. Distinguishing vaccine-induced ITP from coincidental ITP presenting soon after vaccination is impossible at this time. Additional surveillance is needed to determine the true incidence of thrombocytopenia post vaccination. If the incidence of thrombocytopenia post vaccination is higher than that based on available case reports, we anticipate that many more cases will be reported in the coming weeks as a higher proportion of the population is vaccinated. It may be worthwhile to see whether exacerbations of other conditions considered to have an autoimmune pathophysiology occur as well to gain a better understanding of host response to vaccination.

Notwithstanding these concerns, the incidence of symptomatic thrombocytopenia post vaccination is well below the risk of death and morbidity from SARS-CoV-2 infection as also described on the 

Death of Florida doctor after receiving COVID-19 vaccine under investigation. USA Today

Doctor's death after Covid vaccine is being investigated. The New York Times

Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine

Familial thrombocytopenia flare-up following the first dose of mRA-1273 COVID-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children

Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases

The risk of immune thrombocytopenic purpura after vaccination in children and adolescents

Acute immune thrombocytopenia following administration of Shingrix recombinant zoster vaccine

A case-control study to assess the risk of immune thrombocytopenia associated with vaccines

Safety of antisense oligonucleotide and siRNA-based therapeutics

Toxicology of antisense therapeutics

Antibody-induced procoagulant platelets in severe COVID-19 infection

Clinical characteristics, management and outcome of Covid-19-associated immune thrombocytopenia. A French Multicenter Series

Immune thrombocytopenia secondary to COVID-19: a systematic review

Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura